Interim results Q2-2011 for Biotec Pharmacon
(Thomson Reuters ONE) -
Highlights:
ENZYMES - ArcticZymes
* Revenue affected by low deliveries of the lead product SAP to our exclusive
customer and distributor Affymetrix (USB)
* Good growth for the other products
* Signed new multiproduct contracts with PrimerDesign and TATAA Biocenter,
both exposing the ArcticZymes brand name
BETA-GLUCANS
* Good sales growth for beta-glucan bulk products to the dietary supplement
market
* Third animal study confirms that a SBG hydrogel formulation has
statistically significant better wound healing capabilities than a
commercially available active hydrogel
* Suitable packaging container (tube) identified for the first generation SBG
hydrogel - formal stability study ongoing
* Obtained registration of Woulgan® as intended trade name for the first
generation hydrogel
* Commercial partnering process continuing. The opportunity of a more
advanced regulatory positioning (Class III device) is expected to make the
process more time-consuming, without slowing down the actual product
development process
FINANCIAL DEVELOPMENT AND POSITION
* Improvement in pre-tax result by NOK 10.4 million to NOK -8.2 million in
first half of 2011, although with only small year-on-year improvement in the
second quarter
* Cash balance of NOK 42 million per 30 June, 2011
OUTLOOK
* Enzymes: Temporary lower sales expected for SAP - ArcticZymes is working to
resume control over the situation. Good growth expected for other products
* Beta-Glucans: Product development and partnering processes moving on in
concert
Please find attached the full interim report for the second quarter and first
half year 2011.
For further information, please contact:
Svein W. F. Lien - CEO: +47 922 89 323
The company hosts a presentation of the interim results on August 10th at 08:00
at Thon Conference, Vika Atrium, Oslo.
The presentation will also be available as webcast with log on atwww.biotec.no.
This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
Interim_Report_Q2_2011:
http://hugin.info/136141/R/1537197/469146.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Biotec Pharmacon ASA via Thomson Reuters ONE
[HUG#1537197]
Unternehmensinformation / Kurzprofil:
Datum: 09.08.2011 - 18:10 Uhr
Sprache: Deutsch
News-ID 57090
Anzahl Zeichen: 3109
contact information:
Town:
Tromsø
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 169 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Interim results Q2-2011 for Biotec Pharmacon"
steht unter der journalistisch-redaktionellen Verantwortung von
Biotec Pharmacon ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
